LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved for the…
How Are Payer Policies and Physician Preferences Shaping the Prescribing Landscape? The European oral anticoagulation market has undergone a dramatic expansion in the treatment armamentarium in…
Special Report: How Are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms in the United States? is designed to assess and quantify the market impact of the 2014 launches of…
How Can Novel LABA/LAMA Combinations Differentiate Themselves in an Increasingly Crowded Market? Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and…
How Can Novel Biologics Targeting Niche Populations Maximize Uptake in an Increasingly Competitive Marketplace? Although several effective anti-inflammatory agents and bronchodilators are…
What Does This Emerging Trend Hold for Branded Agents? Asthma and chronic obstructive pulmonary disease (COPD) are chronic diseases of the airways affecting millions of Americans and representing…
Amid Substantial Unmet Need, What Clinical Improvements Do Neurologists and Payers Expect of Novel Symptomatic and First-to-Market Disease-Modifying Therapies? Alzheimer’s disease (AD) will pose…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the…
In a Market Dominated by Well-Entrenched, Effective Psychostimulants, What Do Physicians and Payers Identify as Areas for Differentiation? Attention-deficit/hyperactivity disorder (ADHD) is a…
For Neurologists and Payers, What Opportunities Still Exist for Novel Disease-Modifying Therapies in an Increasingly Crowded Market? The relapsing-remitting multiple sclerosis (RR-MS) therapy…
Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…
A Survey of Non-interventional Cardiologists and Managed Care Organization Pharmacy and Medical Directors Atherosclerosis refers to the thickening of arterial walls due to deposition of plaque; it…
What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies? The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming…
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
How Are Payers Reacting to Elevated Costs and How Will the Cost Trend Impact Specific Brands? The nation’s healthcare payers are using multilayered cost and utilization control strategies to rein…